表紙
市場調查報告書
商品編碼
1036309

細胞、基因治療用融化設備的全球市場:產業趨勢、成長預測 (∼2028年)

Global Cell And Gene Therapy Thawing Equipment Market - Industry Trends And Forecast To 2028

出版日期: | 出版商: Data Bridge Market Research Private Limited | 英文 292 Pages | 商品交期: 3-5個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球細胞、基因治療用融化設備的市場規模在預測期間內預計以14.2%的年複合成長率成長。面向了細胞、基因治療的開發的R&D投資增加,醫療費增加等要素促進該市場的成長。

本報告提供全球細胞、基因治療用融化設備的市場調查,市場概要,市場成長的各種影響因素分析,相關法律,市場規模的變化、預測,模式、樣品、類型、用途、終端用戶、各地區/主要國家的明細,企業佔有率,主要企業簡介等彙整資訊。

目錄

第1章 簡介

第2章 市場分類

第3章 摘要整理

第4章 重要考察

第5章 在上游及下游流程的融化設備的使用

第6章 使用融化設備的細胞及基因治療的工作流程

第7章 全球細胞、基因治療用融化設備市場:法律規章

第8章 地區概要

第9章 市場概要

  • 促進因素
  • 阻礙因素
  • 市場機會
  • 課題

第10章 COVID-19的影響

第11章 全球細胞、基因治療用融化設備市場:各種模式

  • 桌面式
  • 可攜式

第12章 全球細胞、基因治療用融化設備市場:各樣品

  • 細胞治療
    • CAR T細胞
    • NK細胞
    • 間質幹細胞
    • TIL (腫瘤浸潤淋巴球)
    • 其他
  • 基因治療
    • 腺病毒
    • 腺結合病毒
    • 慢病毒
    • 腫瘤溶解性病毒
    • 其他

第13章 全球細胞、基因治療用融化設備市場:各類型

  • 自動解凍系統
  • 手動解凍系統

第14章 全球細胞、基因治療用融化設備市場:各用途

  • 上游處理
    • 自動解凍系統
    • 手動解凍系統
  • 下游處理
    • 自動解凍系統
    • 手動解凍系統

第15章 全球細胞、基因治療用融化設備市場:各終端用戶

  • 醫院、診斷實驗室
  • 血庫、輸血中心
  • 研究實驗室、學術機構
  • 生物科技、製藥產業
  • 臍帶血、幹細胞銀行
  • 遺傳基因銀行
  • 其他

第16章 全球細胞、基因治療用融化設備市場:各銷售管道

  • 直接競標
  • 第三方流通經銷商
  • 其他

第17章 全球細胞、基因治療用融化設備市場:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第18章 全球細胞、基因治療用融化設備市場:企業形勢

  • 企業佔有率分析:世界
  • 企業佔有率分析:北美
  • 企業佔有率分析:歐洲
  • 企業佔有率分析:亞太地區

第19章 SWOT分析

第20章 企業簡介

  • MERCK KGAA
  • EPPENDORF AG
  • SARTORIUS AG
  • CYTIVA
  • BARKEY
  • BOEKEL SCIENTIFIC
  • BIOLINE INDIA
  • COOK
  • GENESIS BPS
  • HELMER SCIENTIFIC INC.
  • LABCOLD
  • PLEURISTEM THERAPEUTICS INC.
  • SARSTEDT AG & CO. KG

第21章 問卷調查

第22章 相關報告

目錄

Global cell and gene therapy thawing equipment market is projected to register a CAGR of 14.2% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028

Market Segmentation:

Global Cell and Gene Therapy Thawing Equipment Market, By Modality (Benchtop and Portable), Sample (Cell Therapies and Gene Therapies), Type (Manual Thawing System and Automatic Thawing System), Application (Upstream Processing and Downstream Processing), End User (Blood Banks And Transfusion Centres, Hospitals and Diagnostic Laboratories, Research Laboratories And Academic Institutes, Biotechnology and Pharmaceutical Industry, Cord Blood and Stem Cell Banks, Gene Banks and Others), Distribution Channel (Direct Tender, Third Part Distributor and Others), Country (U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Ireland, Rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel and Rest of Middle East and Africa, Brazil, Argentina and Rest of South America) Industry Trends and Forecast to 2028

Some of the major factors contributing to the growth of the global cell and gene therapy thawing equipment market are:

  • Rise in investment in research and development for development of cell and gene therapies
  • Rising healthcare expenditure

Market Players:

The key market players for global cell and gene therapy thawing equipment market are listed below:

  • Pluristem Therapeutics Inc.
  • Genesis BPS
  • Eppendorf AG
  • Cytiva (A subsidiary of Danaher Corporation)
  • Glenmark Pharmaceutical Inc.
  • USA (A subsidiary of Glenmark)
  • EDGE pharma
  • Cook
  • SARSTEDT AG & Co. KG
  • Barkey
  • Boekel Scientific
  • LABCOLD
  • Sartorious AG
  • Helmer Scientific Inc.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 TYPE LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 VENDOR SHARE ANALYSIS
  • 2.11 MARKET APPLICATION COVERAGE GRID
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 USAGE OF THAWING EQUIPMENT IN UPSTREAM AND DOWNSTREAM PROCESSES

  • 5.1 UPSTREAM PROCESS
  • 5.2 DOWNSTREAM PROCESS

6 CELL AND GENE THERAPY WORKFLOW USING THAWING EQUIPMENT

7 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: REGULATIONS

  • 7.1 CANADA
  • 7.2 THE U.S.
  • 7.3 EUROPE
  • 7.4 GENE THERAPY LEGISLATION IN AUSTRIA
  • 7.5 GENE THERAPY LEGISLATION IN BULGARIA
  • 7.6 JAPAN
  • 7.7 ITALY
  • 7.8 MALAYSIA

8 REGIONAL SUMMARY

9 MARKET OVERVIEW

  • 9.1 DRIVERS
    • 9.1.1 INCREASE IN CASES OF GENETIC DISEASES SUCH AS CYSTIC FIBROSIS AND SICKLE CELL ANEMIA
    • 9.1.2 RISE IN INVESTMENT IN R&D FOR DEVELOPMENT OF CELL AND GENE THERAPIES
    • 9.1.3 GOVERNMENT INITIATIVES FOR INITIATION OF CELL AND GENE THERAPY FIELD
    • 9.1.4 INCREASED IMPLEMENTATION OF ADENO-ASSOCIATED VIRUS
    • 9.1.5 TECHNOLOGICAL ADVANCEMENTS IN THE THAWING SYSTEMS
  • 9.2 RESTRAINTS
    • 9.2.1 RISE IN COST ASSOCIATED WITH CELL AND GENE THERAPY ENGINEERING
    • 9.2.2 RISE OF UNWANTED MUTAGENS
    • 9.2.3 TECHNICAL HINDRANCE FACED IN USING THAWING INSTRUMENTS
    • 9.2.4 STRICT REGULATORY FRAMEWORK
  • 9.3 OPPORTUNITIES
    • 9.3.1 INCREASING PREVALENCE OF CANCER
    • 9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
    • 9.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR
  • 9.4 CHALLENGES
    • 9.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES
    • 9.4.2 LACK OF ACCESSIBILITY

10 IMPACT OF COVID-19 ON GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET

  • 10.1 IMPACT ON PRICE
  • 10.2 IMPACT ON DEMAND
  • 10.3 IMPACT ON SUPPLY CHAIN
  • 10.4 STRATEGIC DECISION FOR MANUFACTURERS
  • 10.5 CONCLUSION

11 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY MODALITY

  • 11.1 OVERVIEW
  • 11.2 BENCH TOP
  • 11.3 PORTABLE

12 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY SAMPLE

  • 12.1 OVERVIEW
  • 12.2 CELL THERAPIES
    • 12.2.1 CAR T CELLS
    • 12.2.2 NK CELLS
    • 12.2.3 MSCS
    • 12.2.4 TILS
    • 12.2.5 OTHERS
  • 12.3 GENE THERAPIES
    • 12.3.1 ADENOVIRUS
    • 12.3.2 ADENO-ASSOCIATED VIRUSES
    • 12.3.3 LENTIVIRUSES
    • 12.3.4 ONCOLYTIC VIRUSES
    • 12.3.5 OTHERS

13 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY TYPE

  • 13.1 OVERVIEW
  • 13.2 AUTOMATIC THAWING SYSTEM
  • 13.3 MANUAL THAWING SYSTEM

14 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY APPLICATION

  • 14.1 OVERVIEW
  • 14.2 UPSTREAM PROCESSING
    • 14.2.1 AUTOMATIC THAWING SYSTEM
    • 14.2.2 MANUAL THAWING SYSTEM
  • 14.3 DOWNSTREAM PROCESSING
    • 14.3.1 AUTOMATIC THAWING SYSTEM
    • 14.3.2 MANUAL THAWING SYSTEM

15 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY END USER

  • 15.1 OVERVIEW
  • 15.2 HOSPITALS AND DIAGNOSTIC LABORATORIES
  • 15.3 BLOOD BANKS AND TRANSFUSION CENTERS
  • 15.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES
  • 15.5 BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRY
  • 15.6 CORD BLOOD AND STEM CELL BANKS
  • 15.7 GENE BANKS
  • 15.8 OTHERS

16 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY DISTRIBUTION CHANNEL

  • 16.1 OVERVIEW
  • 16.2 DIRECT TENDER
  • 16.3 THIRD PARTY DISTRIBUTORS
  • 16.4 OTHERS

17 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY REGION

  • 17.1 OVERVIEW
  • 17.2 NORTH AMERICA
    • 17.2.1 U.S.
    • 17.2.2 CANADA
    • 17.2.3 MEXICO
  • 17.3 EUROPE
    • 17.3.1 GERMANY
    • 17.3.2 FRANCE
    • 17.3.3 U.K.
    • 17.3.4 ITALY
    • 17.3.5 SPAIN
    • 17.3.6 RUSSIA
    • 17.3.7 TURKEY
    • 17.3.8 BELGIUM
    • 17.3.9 NETHERLANDS
    • 17.3.10 SWITZERLAND
    • 17.3.11 LUXEMBOURG
    • 17.3.12 REST OF EUROPE
  • 17.4 ASIA-PACIFIC
    • 17.4.1 CHINA
    • 17.4.2 INDIA
    • 17.4.3 JAPAN
    • 17.4.4 SOUTH KOREA
    • 17.4.5 AUSTRALIA
    • 17.4.6 SINGAPORE
    • 17.4.7 THAILAND
    • 17.4.8 MALAYSIA
    • 17.4.9 INDONESIA
    • 17.4.10 PHILIPPINES
    • 17.4.11 REST OF ASIA PACIFIC
  • 17.5 SOUTH AMERICA
    • 17.5.1 BRAZIL
    • 17.5.2 ARGENTINA
    • 17.5.3 REST OF SOUTH AMERICA
  • 17.6 MIDDLE EAST AND AFRICA
    • 17.6.1 SOUTH AFRICA
    • 17.6.2 SAUDI ARABIA
    • 17.6.3 U.A.E.
    • 17.6.4 EGYPT
    • 17.6.5 ISRAEL
    • 17.6.6 REST OF MIDDLE EAST AFRICA

18 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, COMPANY LANDSCAPE

  • 18.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 18.3 COMPANY SHARE ANALYSIS: EUROPE
  • 18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

19 SWOT ANALYSIS

20 COMPANY PROFILE

  • 20.1 MERCK KGAA
    • 20.1.1 COMPANY SNAPSHOT
    • 20.1.2 REVENUE ANALYSIS
    • 20.1.3 PRODUCT PORTFOLIO
    • 20.1.4 RECENT DEVELOPMENTS
  • 20.2 EPPENDORF AG
    • 20.2.1 COMPANY SNAPSHOT
    • 20.2.2 REVENUE ANALYSIS
    • 20.2.3 PRODUCT PORTFOLIO
    • 20.2.4 RECENT DEVELOPMENTS
  • 20.3 SARTORIUS AG
    • 20.3.1 COMPANY SNAPSHOT
    • 20.3.2 REVENUE ANALYSIS
    • 20.3.3 PRODUCT PORTFOLIO
    • 20.3.4 RECENT DEVELOPMENT
  • 20.4 CYTIVA (A SUBSIDIARY OF DANAHER CORPORATION)
    • 20.4.1 COMPANY SNAPSHOT
    • 20.4.2 REVENUE ANALYSIS
    • 20.4.3 PRODUCT PORTFOLIO
    • 20.4.4 .RECENT DEVELOPMENTS
  • 20.5 BARKEY
    • 20.5.1 COMPANY SNAPSHOT
    • 20.5.2 PRODUCT PORTFOLIO
    • 20.5.3 RECENT DEVELOPMENTS
  • 20.6 BOEKEL SCIENTIFIC
    • 20.6.1 COMPANY SNAPSHOT
    • 20.6.2 PRODUCT PORTFOLIO
    • 20.6.3 RECENT DEVELOPMENT
  • 20.7 BIOLINE INDIA
    • 20.7.1 COMPANY SNAPSHOT
    • 20.7.2 PRODUCT PORTFOLIO
    • 20.7.3 RECENT DEVELOPMENTS
  • 20.8 COOK
    • 20.8.1 COMPANY SNAPSHOT
    • 20.8.2 PRODUCT PORTFOLIO
    • 20.8.3 RECENT DEVELOPMENT
  • 20.9 GENESIS BPS
    • 20.9.1 COMPANY SNAPSHOT
    • 20.9.2 PRODUCT PORTFOLIO
    • 20.9.3 RECENT DEVELOPMENTS
  • 20.10 HELMER SCIENTIFIC INC.
    • 20.10.1 COMPANY SNAPSHOT
    • 20.10.2 PRODUCT PORTFOLIO
    • 20.10.3 RECENT DEVELOPMENTS
  • 20.11 LABCOLD
    • 20.11.1 COMPANY SNAPSHOT
    • 20.11.2 PRODUCT PORTFOLIO
    • 20.11.3 RECENT DEVELOPMENTS
  • 20.12 PLEURISTEM THERAPEUTICS INC.
    • 20.12.1 COMPANY SNAPSHOT
    • 20.12.2 REVENUE ANALYSIS
    • 20.12.3 PRODUCT PORTFOLIO
    • 20.12.4 RECENT DEVELOPMENTS
  • 20.13 SARSTEDT AG & CO. KG
    • 20.13.1 COMPANY SNAPSHOT
    • 20.13.2 PRODUCT PORTFOLIO
    • 20.13.3 RECENT DEVELOPMENTS

21 QUESTIONNAIRE

22 RELATED REPORTS

LIST OF FIGURES

  • FIGURE 1 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SEGMENTATION 38
  • FIGURE 2 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: DATA TRIANGULATION 41
  • FIGURE 3 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: DROC ANALYSIS 42
  • FIGURE 4 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 43
  • FIGURE 5 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: COMPANY RESEARCH ANALYSIS 43
  • FIGURE 6 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: MULTIVARIATE MODELLING 44
  • FIGURE 7 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: INTERVIEW DEMOGRAPHICS 46
  • FIGURE 8 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: DBMR MARKET POSITION GRID 47
  • FIGURE 9 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: VENDOR SHARE ANALYSIS 48
  • FIGURE 10 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: MARKET APPLICATION COVERAGE GRID 49
  • FIGURE 11 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SEGMENTATION 53
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028 54
  • FIGURE 13 INCREASE IN CASES OF GENETIC DISEASES SUCH AS CARDIAC AILMENTS, CYSTIC FIBROSIS AND AIDS IS EXPECTED TO DRIVE THE GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 55
  • FIGURE 14 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET IN 2021 & 2028 55
  • FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR THE CELL AND GENE THERAPY THAWING EQUIPMENT MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028 56
  • FIGURE 16 PESTEL ANALYSIS 57
  • FIGURE 17 PORTERS FIVE FORCES MODEL 58
  • FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET 67
  • FIGURE 19 INCIDENCE OF CYSTIC FIBROSIS OBSERVED IN THE COUNTRIES 69
  • FIGURE 20 PREVALENCE OF SICKLE CELL ANEMIA IN AFRICA AND EUROPE 69
  • FIGURE 21 NEW CANCER CASES WORLDWIDE, (2018) (IN MILLION) 73
  • FIGURE 22 GLOBAL CANCER INCIDENCE (2018) 74
  • FIGURE 23 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY, 2020 82
  • FIGURE 24 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY, 2021-2028 (USD MILLION) 83
  • FIGURE 25 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY, CAGR (2021-2028) 83
  • FIGURE 26 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY, LIFELINE CURVE 84
  • FIGURE 27 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY SAMPLE, 2020 88
  • FIGURE 28 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY SAMPLE, 2021-2028 (USD MILLION) 89
  • FIGURE 29 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY SAMPLE, CAGR (2021-2028) 89
  • FIGURE 30 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY SAMPLE, LIFELINE CURVE 90
  • FIGURE 31 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY TYPE, 2020 96
  • FIGURE 32 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY TYPE, 2021-2028 (USD MILLION) 97
  • FIGURE 33 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY TYPE, CAGR (2021-2028) 97
  • FIGURE 34 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY TYPE, LIFELINE CURVE 98
  • FIGURE 35 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY APPLICATION, 2020 102
  • FIGURE 36 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY APPLICATION, 2021-2028 (USD MILLION) 103
  • FIGURE 37 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY APPLICATION, CAGR (2021-2028) 103
  • FIGURE 38 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY APPLICATION, LIFELINE CURVE 104
  • FIGURE 39 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY END USER, 2020 108
  • FIGURE 40 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY END USER, 2021-2028 (USD MILLION) 109
  • FIGURE 41 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY END USER, CAGR (2021-2028) 109
  • FIGURE 42 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY END USER, LIFELINE CURVE 110
  • FIGURE 43 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, 2020 119
  • FIGURE 44 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION) 120
  • FIGURE 45 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028) 120
  • FIGURE 46 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 121
  • FIGURE 47 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 126
  • FIGURE 48 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY REGION (2020) 127
  • FIGURE 49 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY REGION (2021 & 2028) 127
  • FIGURE 50 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY REGION (2020 & 2028) 128
  • FIGURE 51 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 128
  • FIGURE 52 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 131
  • FIGURE 53 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020) 132
  • FIGURE 54 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2021 & 2028) 132
  • FIGURE 55 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020 & 2028) 133
  • FIGURE 56 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 133
  • FIGURE 57 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 147
  • FIGURE 58 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020) 148
  • FIGURE 59 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2021 & 2028) 148
  • FIGURE 60 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020 & 2028) 149
  • FIGURE 61 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 149
  • FIGURE 62 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 188
  • FIGURE 63 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020) 189
  • FIGURE 64 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2021 & 2028) 189
  • FIGURE 65 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020 & 2028) 190
  • FIGURE 66 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 190
  • FIGURE 67 SOUTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 226
  • FIGURE 68 SOUTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020) 227
  • FIGURE 69 SOUTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2021 & 2028) 227
  • FIGURE 70 SOUTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020 & 2028) 228
  • FIGURE 71 SOUTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 228
  • FIGURE 72 MIDDLE EAST AND AFRICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 240
  • FIGURE 73 MIDDLE EAST AND AFRICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020) 241
  • FIGURE 74 MIDDLE EAST AND AFRICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2021 & 2028) 241
  • FIGURE 75 MIDDLE EAST AND AFRICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020 & 2028) 242
  • FIGURE 76 MIDDLE EAST AND AFRICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 242
  • FIGURE 77 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENTMARKET: COMPANY SHARE 2020 (%) 262
  • FIGURE 78 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENTMARKET: COMPANY SHARE 2020 (%) 263
  • FIGURE 79 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENTMARKET: COMPANY SHARE 2020 (%) 264
  • FIGURE 80 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENTMARKET: COMPANY SHARE 2020 (%) 265
  • FIGURE 81 COMPANY SHARE ANALYSIS 268
  • FIGURE 82 COMPANY SHARE ANALYSIS 271
  • FIGURE 83 COMPANY SHARE ANALYSIS 274
  • FIGURE 84 COMPANY SHARE ANALYSIS 276